Thermo Fisher Scientific Inc (NYSE:TMO) CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the transaction, the chief executive officer now owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of Thermo Fisher Scientific Inc (TMO) opened at $190.17 on Friday. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $201.20. The firm has a market capitalization of $76,030.00, a price-to-earnings ratio of 20.78, a price-to-earnings-growth ratio of 1.73 and a beta of 1.08. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same period in the prior year, the business earned $2.03 EPS. The business’s revenue for the quarter was up 13.9% compared to the same quarter last year. sell-side analysts predict that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.19%.

COPYRIGHT VIOLATION NOTICE: “Marc N. Casper Sells 50,000 Shares of Thermo Fisher Scientific Inc (TMO) Stock” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/19/marc-n-casper-sells-50000-shares-of-thermo-fisher-scientific-inc-tmo-stock.html.

A number of equities analysts recently issued reports on TMO shares. Leerink Swann boosted their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a report on Monday, October 9th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price objective for the company in a report on Thursday, September 21st. Cowen and Company restated an “outperform” rating and set a $220.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Deutsche Bank AG set a $226.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. Finally, BidaskClub cut Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $205.71.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of Nova Scotia Trust Co. purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $106,000. Proficio Capital Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 71.5% during the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after purchasing an additional 253 shares during the last quarter. Cribstone Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 8.7% during the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after purchasing an additional 50 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $113,000. Finally, Chicago Partners Investment Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $108,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.